APA (7th ed.) Citation

Nauck, M. (2016). Incretin therapies: Highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, obesity & metabolism, 18(3), 203-216. https://doi.org/10.1111/dom.12591

Chicago Style (17th ed.) Citation

Nauck, M. "Incretin Therapies: Highlighting Common Features and Differences in the Modes of Action of Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors." Diabetes, Obesity & Metabolism 18, no. 3 (2016): 203-216. https://doi.org/10.1111/dom.12591.

MLA (9th ed.) Citation

Nauck, M. "Incretin Therapies: Highlighting Common Features and Differences in the Modes of Action of Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors." Diabetes, Obesity & Metabolism, vol. 18, no. 3, 2016, pp. 203-216, https://doi.org/10.1111/dom.12591.